Dulaglutide & Ketamine: Trulicity Compatibility
Trulicity (Dulaglutide) — GLP-1 receptor agonist (diabetes)
Verdict at Tovani Health
Fully compatible; same profile as semaglutide.
Dulaglutide (Trulicity) and ketamine have no clinically significant interaction. Trulicity is FDA-approved for type 2 diabetes only — it doesn't carry the suicidal-ideation warning that applied to the weight-loss-approved GLP-1s, because that FDA class rule covers only chronic weight management drugs acting on the CNS. The interaction profile with ketamine is identical to the rest of the GLP-1 receptor agonist class: peripheral mechanism, no shared metabolism, no central additive effects.
If you take Trulicity regularly and are considering at-home ketamine therapy, the combination is generally safe at therapeutic doses. This page covers the brief pharmacologic context and what we do at intake.
How Trulicity interacts with ketamine
Dulaglutide is a once-weekly GLP-1 receptor agonist with a fusion-protein backbone (linked to an Fc fragment) that extends its half-life. Same downstream effects as semaglutide and liraglutide: slowed gastric emptying, enhanced insulin secretion, reduced appetite. No CYP metabolism; cleared by general protein catabolism. No pharmacokinetic or pharmacodynamic overlap with ketamine.
What we do at intake
Continue your weekly Trulicity injection. Tell us your dose, your last escalation date, and whether GI side effects are an issue. The off-label use of Trulicity for weight loss is less common than with semaglutide or tirzepatide — if you're using it that way, let us know so we can understand your full treatment context.
Bottom line
Dulaglutide (Trulicity) and ketamine have no clinically significant interaction. Trulicity is FDA-approved for type 2 diabetes only — it doesn't carry the suicidal-ideation warning that applied to the weight-loss-approved GLP-1s, because that FDA class rule covers only chronic weight management drugs acting on the CNS. The interaction profile with ketamine is identical to the rest of the GLP-1 receptor agonist class: peripheral mechanism, no shared metabolism, no central additive effects.
Frequently Asked Questions
Is Trulicity used for weight loss too?
Off-label, yes — but less commonly than semaglutide or tirzepatide. The FDA approval is for type 2 diabetes only, and Trulicity didn't have the FDA suicidal-ideation warning that applied to the weight-loss-indicated GLP-1s.
Does Trulicity have a different interaction profile than Ozempic for ketamine?
No clinically meaningful difference. Both slow gastric emptying; neither interacts at the NMDA receptor; neither shares metabolic pathways with ketamine.
I'm switching from Trulicity to Ozempic next month — should I delay ketamine until I'm stable on the new one?
Generally no. Both are GLP-1 RAs with very similar profiles. We can proceed and adjust if you have new GI symptoms during the transition. If your prescriber expects a noticeable change in side-effect burden during the switch, tell us — we'll plan sessions for the more-stable weeks.
Did Trulicity ever carry a suicidal-ideation warning?
No — Trulicity is approved for diabetes only, not chronic weight management, so the FDA class rule that applied to Saxenda, Wegovy, and Zepbound never applied to Trulicity. The January 2026 FDA action removed that warning from the three drugs that had it. Trulicity was never affected.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Trulicity (Dulaglutide) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs. et al.. International Journal of Clinical Pharmacy. 2026. PMID: 41739406
Pharmacovigilance analysis across the GLP-1 class including dulaglutide — no class-wide suicidality signal.
- Implications of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Mood Disorders and Suicide Risk. et al.. Biological Psychiatry. 2026. PMID: 42069105
Class-wide synthesis of evidence on GLP-1 RA effects on mood.
- Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI.. Clinical Pharmacokinetics. 2016. PMID: 27028535
Ketamine pharmacokinetics reference — establishes that the protein-cleared dulaglutide and CYP-metabolized ketamine have no shared elimination pathway.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 27, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.